(VIANEWS) – CONTEXTVISION (CONTX.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| CONTEXTVISION (CONTX.OL) | kr7.14 | 3.46% | 61.1% |
| BOIRON (BOI.PA) | €40.55 | 2.77% | 8.64% |
| ESSILORLUXOTTICA (EL.PA) | €175.32 | 1.92% | 6.44% |
| SARTORIUS STED BIO (DIM.PA) | €187.55 | 0.87% | 18.66% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. CONTEXTVISION (CONTX.OL)
3.46% Forward Dividend Yield and 61.1% Return On Equity
ContextVision AB (publ), a medical technology software company, provides image analysis and imaging for medical systems in Asia, Europe, and the United States. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and veterinary. Its products include Rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; Rivent Mobile, an enhancing ultrasound image for the handheld ultrasound devices using mobile phones and tablets; and Rivent 3D, an image enhancement product for 3D ultrasound. The company also provides Altumira/Altumira Plus, a platform for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI. The company was founded in 1983 and is headquartered in Stockholm, Sweden.
Earnings Per Share
As for profitability, CONTEXTVISION has a trailing twelve months EPS of kr0.46.
PE Ratio
CONTEXTVISION has a trailing twelve months price to earnings ratio of 15.52. Meaning, the purchaser of the share is investing kr15.52 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 61.1%.
Volume
Today’s last reported volume for CONTEXTVISION is 3273 which is 89.37% below its average volume of 30802.
Moving Average
CONTEXTVISION’s worth is way under its 50-day moving average of kr8.37 and way under its 200-day moving average of kr8.72.
Volatility
CONTEXTVISION’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.54%, a negative 0.07%, and a positive 1.99%.
CONTEXTVISION’s highest amplitude of average volatility was 2.25% (last week), 2.57% (last month), and 1.99% (last quarter).
More news about CONTEXTVISION.
2. BOIRON (BOI.PA)
2.77% Forward Dividend Yield and 8.64% Return On Equity
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €2.74.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 14.8. Meaning, the purchaser of the share is investing €14.8 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.64%.
More news about BOIRON.
3. ESSILORLUXOTTICA (EL.PA)
1.92% Forward Dividend Yield and 6.44% Return On Equity
EssilorLuxottica Société anonyme engages in design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses in Europe, Middle East, Africa, Latin America, Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Crizal, Essilor, Eyezen, Stellest, Xperio, Optifog, Satisloh, Barberini, Shamir, Nikon, KODAK Lens, Oakley, OPTIFOG, Ray-Ban, Transitions, Vailux, and Xperio brands. It also provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Alain Mikli, Costa del Mar, Native Eyewear, Luxottica, Sferoflex, Heritage, Sensaya, Miki Ninn, DbyD, Unofficial and Seen, Arnette, Vogue Eyewear, Bolon, Molsion, and Ossé, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of physical stores or its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ESSILORLUXOTTICA has a trailing twelve months EPS of €5.23.
PE Ratio
ESSILORLUXOTTICA has a trailing twelve months price to earnings ratio of 33.52. Meaning, the purchaser of the share is investing €33.52 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.44%.
Volume
Today’s last reported volume for ESSILORLUXOTTICA is 144569 which is 61.99% below its average volume of 380437.
Yearly Top and Bottom Value
ESSILORLUXOTTICA’s stock is valued at €175.32 at 01:30 EST, under its 52-week high of €188.40 and way above its 52-week low of €155.15.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ESSILORLUXOTTICA’s stock is considered to be oversold (<=20).
More news about ESSILORLUXOTTICA.
4. SARTORIUS STED BIO (DIM.PA)
0.87% Forward Dividend Yield and 18.66% Return On Equity
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; batch and intensified chromatography systems for smaller molecules applications, such as oligonucleotides, peptides, and insulin; and recombinant albumin based solutions. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of medications, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €6.9.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 27.18. Meaning, the purchaser of the share is investing €27.18 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.66%.
Yearly Top and Bottom Value
SARTORIUS STED BIO’s stock is valued at €187.55 at 01:30 EST, way under its 52-week high of €363.80 and way higher than its 52-week low of €160.55.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SARTORIUS STED BIO’s EBITDA is 94.32.
Sales Growth
SARTORIUS STED BIO’s sales growth for the current quarter is negative 4.1%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SARTORIUS STED BIO’s stock is considered to be oversold (<=20).
More news about SARTORIUS STED BIO.
